Vor Financial Statements From 2010 to 2025

VOR Stock  USD 2.09  0.04  1.95%   
Vor Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vor Biopharma's valuation are provided below:
Market Capitalization
256.2 M
Earnings Share
(1.51)
There are over one hundred nineteen available fundamental trend indicators for Vor Biopharma, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Vor Biopharma's current fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 07/24/2025, Market Cap is likely to drop to about 72.5 M. In addition to that, Enterprise Value is likely to drop to about 24.8 M
Check Vor Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vor Biopharma's main balance sheet or income statement drivers, such as Net Interest Income of 4.5 M, Interest Income of 4.5 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.75. Vor financial statements analysis is a perfect complement when working with Vor Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Vor Stock
Check out the analysis of Vor Biopharma Correlation against competitors.
To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide.

Vor Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets152.4 M142.9 M70.6 M
Slightly volatile
Short and Long Term Debt Total27 M31.8 M14.3 M
Slightly volatile
Other Current Liabilities6.9 M12.3 M4.8 M
Slightly volatile
Total Current Liabilities12.2 M18.6 M9.5 M
Slightly volatile
Property Plant And Equipment Net30.5 M41.6 M14.1 M
Slightly volatile
Current Deferred Revenue5.1 M7.3 M3.5 M
Slightly volatile
Accounts Payable1.4 M1.5 M650.3 K
Slightly volatile
Cash54.5 M81.9 M25.5 M
Slightly volatile
Non Current Assets Total35.1 M46.4 M16.2 M
Slightly volatile
Cash And Short Term Investments113.6 M91.9 M52.7 M
Slightly volatile
Common Stock Shares Outstanding46 M68.7 M24 M
Slightly volatile
Liabilities And Stockholders Equity152.4 M142.9 M70.6 M
Slightly volatile
Non Current Liabilities Total20.3 M27.6 M9.4 M
Slightly volatile
Other Current Assets3.7 M4.6 M1.7 M
Slightly volatile
Other Stockholder Equity293.4 M553.6 M135.2 M
Slightly volatile
Total Liabilities32.4 M46.2 M18.8 M
Slightly volatile
Property Plant And Equipment Gross34.6 M52.8 M15.9 M
Slightly volatile
Short and Long Term Debt3.6 MM4.4 M
Slightly volatile
Total Current Assets117.3 M96.5 M54.4 M
Slightly volatile
Capital Stock12.3 K13 K8.3 M
Pretty Stable
Short Term Debt5.3 M8.4 M4.5 M
Pretty Stable
Property Plant Equipment9.3 M14.5 M4.9 M
Slightly volatile
Non Currrent Assets Other4.2 M4.8 M2.6 M
Slightly volatile
Other Assets4.8 M6.1 MM
Slightly volatile
Common Stock Total Equity4.4 K8.1 K2.6 K
Slightly volatile
Capital Lease Obligations31.4 M31.8 M22.3 M
Slightly volatile
Common StockK13 K3.1 K
Slightly volatile
Capital Surpluse451 M544.6 M381.2 M
Slightly volatile
Non Current Liabilities Other28.5 M41 M20.9 M
Slightly volatile

Vor Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.4 M3.5 M1.6 M
Slightly volatile
Selling General Administrative19.9 M27.9 M9.4 M
Slightly volatile
Other Operating Expenses73.3 M121.2 M35.2 M
Slightly volatile
Research Development53.4 M93.3 M25.8 M
Slightly volatile
Cost Of Revenue3.4 M3.5 M1.6 M
Slightly volatile
Total Operating Expenses73.3 M121.2 M35.2 M
Slightly volatile
Reconciled Depreciation1.8 M3.5 M837 K
Slightly volatile
Preferred Stock And Other Adjustments982.4 K1.1 M1.2 M
Slightly volatile
Non Operating Income Net Other793.6 K1.5 M399.5 K
Slightly volatile
Selling And Marketing Expenses2.8 M3.1 M3.4 M
Slightly volatile

Vor Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net BorrowingsM2.2 M2.4 M
Slightly volatile
Stock Based Compensation6.3 M9.8 M2.9 M
Slightly volatile
Begin Period Cash Flow43.4 M33.8 M20.5 M
Slightly volatile
Depreciation1.8 M3.5 M855.8 K
Slightly volatile
Other Non Cash Items2.5 M3.9 M1.7 M
Slightly volatile
Capital Expenditures217.6 K229 K1.6 M
Slightly volatile
Total Cash From Financing Activities80 M53.4 M38 M
Slightly volatile
End Period Cash Flow56.5 M84.4 M26.5 M
Slightly volatile
Change To Netincome12.9 M12.3 M4.2 M
Slightly volatile
Change To Liabilities1.9 M1.3 M839.2 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.06170.06495.9734
Slightly volatile
Payables Turnover1.812.34421.3645
Slightly volatile
Cash Per Share1.881.3381.2263
Slightly volatile
Days Payables Outstanding148156639
Slightly volatile
Income Quality0.690.85240.7398
Slightly volatile
Current Ratio7.065.18524.3631
Slightly volatile
Capex Per Share0.00320.00330.0409
Slightly volatile
Interest Debt Per Share0.450.46330.7566
Slightly volatile
Debt To Assets0.210.22282.5719
Slightly volatile
Days Of Payables Outstanding148156639
Slightly volatile
Ebt Per Ebit1.160.96481.2593
Slightly volatile
Long Term Debt To Capitalization0.170.140.2217
Slightly volatile
Quick Ratio7.065.18524.3631
Slightly volatile
Net Income Per E B T1.111.131.048
Very volatile
Cash Ratio3.484.4032.1802
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.00231.0758
Very volatile
Debt Ratio0.210.22282.5719
Slightly volatile

Vor Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap72.5 M76.3 MB
Slightly volatile
Enterprise Value24.8 M26.1 M994.3 M
Slightly volatile

Vor Fundamental Market Drivers

Cash And Short Term Investments91.9 M

Vor Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vor Biopharma Financial Statements

Vor Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Vor Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Vor Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vor Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue7.3 M5.1 M
Cost Of Revenue3.5 M3.4 M

Pair Trading with Vor Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vor Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vor Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Vor Stock

  0.72VRDN Viridian TherapeuticsPairCorr
  0.63MRK Merck Company Earnings Call This WeekPairCorr
  0.67PFE Pfizer IncPairCorr
  0.77MRVI Maravai LifesciencesPairCorr
The ability to find closely correlated positions to Vor Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vor Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vor Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vor Biopharma to buy it.
The correlation of Vor Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vor Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vor Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vor Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Vor Stock Analysis

When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.